Cross-linking transepithelial (CXL TE): our experience

Poster Details

First Author: A.Laborante ITALY

Co Author(s):    C. Longo   E. Mazzilli   M. Gaspari        

Abstract Details

Purpose:

to evaluate pain test 0-10 ( Numeric Pain Intensity Scale I, Numeric Rating Scale-NRS), uncorrected visual acuity (UCVA), best spectacle corrected visual acuity (BSCVA),the keratometric parameters and comatic aberration were calculated after Cross-Linkin Transepithelial ( CLX TE) using RICROLIN TE (Riboflavin 0,1% and Enhancer)

Setting:

Ophthalmology Departement, IRCCS- " Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy.

Methods:

30 eyes of 30 patients with keratoconus 2°-3° stage ( according to Krumeich) was treated with CLX TE ( Riboflavin0,1 % + trishydroxymethhylaminomethane + ethylenediaminetetraacetic acid). Laser CSO CBM Vega was used. Intensity pain, UCVA, BSCVA, keratometric and comatic aberration parameters were calculated in preoperatory and after six months and one year posttreatment . Advantages of transepithelial cross-linking: it doesn’t need operating room, corneal thickness ? 400 ?, easier technique, pre-treatment VA maintenance, better patient compliance – children, no post treatment pain, no complications derived from disepithelization.

Results:

no pain, USCVA improved of 2 lines and BSCVA improved of 3 lines after six months the average K improved by 0,5±0,15 Diopters after 6 months and by 0,75±0,20 Diopters after 12 months. Comatic Aberration 2.42µm±0.87µm during pretretment,1.82±0.97µm after 6 months and 1.75µm±0.87 after 12 months. the comatic aberration improved of the 50%, stable of the 38%. The Cross-Linking technique works at 100 microns depth.

Conclusions:

The preliminary study is as safe and effective. Further studies are warranted to determine the long term outcomes. FINANCIAL DISCLOSURE?: No